Kenya: Targets 50% Essential Medicines Local Production by 2030

• Kenya aims to locally produce 50% of its essential health products by 2030, as outlined in its 2026-2030 Health Products and Technologies Local Manufacturing Strategy.
• The government reports 13 new pharmaceutical companies have commenced operations in Kenya, with some already exporting medicines and other health products.
• The Pharmacy and Poisons Board has removed over 2,200 substandard, falsified, or non-compliant products from the market through intensified surveillance.
• Kenya is advancing its regulatory system towards World Health Organization Maturity Level 3 to strengthen quality controls and consumer protection.
• Health Cabinet Secretary Aden Duale highlighted the strategy's role in building a resilient health system and reducing import dependency.

The regulatory push is aimed at ensuring that increased local production is matched by stronger quality controls and consumer protection.

Kenya has set an ambitious target to locally produce at least half of its essential health products by the year 2030. This objective is a cornerstone of the nation's 2026-2030 Health Products and Technologies Local Manufacturing Strategy, which aims to significantly reduce reliance on imports and bolster the country's pharmaceutical security. The strategy is designed to expand domestic pharmaceutical production capabilities while simultaneously enhancing regulatory oversight and improving access to high-quality medicines for its citizens.

Health Cabinet Secretary Aden Duale underscored that this comprehensive strategy forms a critical part of broader governmental efforts to cultivate a more resilient health system. This proactive approach seeks to mitigate Kenya's vulnerability to potential disruptions in the global supply chains for medicines and other vital health products. The initiative gains particular urgency given that Africa currently imports over 70 percent of the health products it consumes, a statistic highlighted by the Ministry of Health (MoH). In a tangible sign of progress, the government has reported the commencement of operations by 13 new pharmaceutical companies within Kenya, with some of these entities already engaged in exporting medicines and other health products. This expansion is anticipated to fortify local supply chains and create new avenues for Kenyan manufacturers to penetrate regional markets.

Alongside the strategic push for increased domestic manufacturing, Kenya is significantly intensifying its surveillance of medicines and other health products available in the market. The Pharmacy and Poisons Board (PPB) has notably stepped up its market monitoring activities, leading to the removal of more than 2,200 substandard, falsified, and non-compliant products from circulation, as confirmed by the Ministry of Health. This rigorous enforcement demonstrates a clear commitment to safeguarding public health and ensuring product integrity.

Furthermore, Kenya is actively working to elevate its regulatory system to World Health Organization (WHO) Maturity Level 3. This internationally recognized benchmark is specifically designed to enhance the capacity and overall effectiveness of national medicines regulatory systems. The regulatory push is aimed at ensuring that increased local production is matched by stronger quality controls and consumer protection, thereby ensuring that locally manufactured products meet stringent global standards.

The broader context for Kenya's pharmaceutical policy reveals a continent grappling with uneven manufacturing capabilities, where approximately 85 percent of Africa's pharmaceutical manufacturing facilities are concentrated in just eight countries, according to Ministry of Health data. Kenya's strategic framework, therefore, seeks to empower its domestic manufacturers not only to fulfill a larger proportion of national demand but also to develop the competitive capacity required for success in both regional and international markets.

These critical issues were central to discussions at the five-day PharmaReg AfriSummit 2026, held under the theme "Building the Bridge of Health." The summit attracted over 450 health professionals, regulators, pharmaceutical industry representatives, and development partners from across Africa and beyond. Key topics addressed included pharmaceutical regulation, the promotion of local manufacturing, and the advancement of Universal Health Coverage. The Kenyan government emphasized that greater regulatory cooperation among African nations will be indispensable for expanding access to safe and quality health products, while simultaneously fostering the sustainable growth of the continent's pharmaceutical industry.

Lawyers and compliance officers advising pharmaceutical companies in Kenya should closely monitor the implementation of the 2026-2030 local manufacturing strategy, as it signals increased regulatory scrutiny, heightened quality control expectations, and potential shifts in market access and compliance requirements from the Pharmacy and Poisons Board, particularly with the push towards WHO Maturity Level 3.

Source: Reporting based on recent industry coverage.